Solae believes soy claim will withstand reevaluation

by Jeff Gelski
Share This:

ST. LOUIS — The Solae Co. is confident science provides adequate substantiation for a 1999 soy protein and heart health claim. The Food and Drug Administration in a Dec. 21 Federal Register notice said it intends to reevaluate the scientific evidence for the claim.

"The relationship between soy protein consumption and the lowering of cholesterol – and thus decreasing the risk of heart disease – has been established in dozens of studies," St. Louis-based Solae said in response to a Food Business News request for comment. "Solae is confident the F.D.A. will come to the same conclusion as Solae and consumers everywhere: Consuming soy protein can be an important part of daily nutrition and maintaining a healthy heart."

In the health claim issued on Oct. 26, 1999, the F.D.A. said soy protein included in a diet low in saturated fat and cholesterol may reduce the risk of coronary heart disease by lowering blood cholesterol levels.

"Since authorizing this health claim, numerous studies have evaluated the relationship between soy protein and coronary heart disease, and the findings of these studies are inconsistent," the F.D.A. said in its Dec. 21 notice.

The F.D.A. will accept comments until Feb. 19. Solae said it plans to send comments to the F.D.A.

As evidence for the need for reevaluation, the F.D.A. pointed to research at the Tufts-New England Medical Center Evidence-based Practice Center, Boston, that was reported on in an Agency for Healthcare Research and Quality publication in July 2005. The study concluded soy products appear to exert a small benefit on low-density lipoprotein (L.D.L.) cholesterol.

"However, it is not clear whether soy protein (versus other types of soy products) was responsible for such a benefit," the F.D.A. said. "The A.H.R.Q. report included studies that evaluated substances in addition to soy protein (e.g., isoflavones).

"In addition, the A.H.R.Q. report used markers of cardiac functions (e.g., triglycerides, endothelial functions, oxidized L.D.L.) that are not validated surrogate endpoints recognized by the agency for heart disease risk."

The F.D.A. said it will evaluate scientific evidence to determine if it meets the significant scientific agreement standard needed for a health claim.

The F.D.A. in the Dec. 21 Federal Register notice also said it plans to reevaluate a health claim for dietary lipids (fat) and cancer along with two qualified health claims, one involving antioxidant vitamins and risk of certain cancers and the other involving selenium and certain cancers.

"The agency is undertaking a reevaluation of the scientific basis for these authorized health claims and qualified health claims because of new scientific evidence that has emerged for these substance-disease relationships," the F.D.A. said of all four claims, including the soy claim. "The new scientific evidence may have the effect of weakening the substance-disease relationship for these authorized health claims and either strengthening or weakening the scientific support for the substance-disease relationship for these qualified health claims."

Comment on this Article
We welcome your thoughtful comments. Please comply with our Community rules.








The views expressed in the comments section of Food Business News do not reflect those of Food Business News or its parent company, Sosland Publishing Co., Kansas City, Mo. Concern regarding a specific comment may be registered with the Editor by clicking the Report Abuse link.